IMMIX BIOPHARMA, INC. Diluted Shares Outstanding (Weighted Average)
IMMIX BIOPHARMA, INC. (IMMX) reported Diluted Shares Outstanding (Weighted Average) of 63.77 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 63.77M shares, a 112.69% increase year-over-year.
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 55.37M shares, a 86.42% increase year-over-year.
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 40.22M shares, a 36.06% increase year-over-year.
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 31.93M shares, a 8.50% increase year-over-year.
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 32.97M shares, a 16.55% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 28.29M shares, a 63.11% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 17.34M shares, a 24.87% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 13.89M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 63.77M shares 10-Q · filed 2026-08-07 | 59.59M shares 10-Q · filed 2026-08-07 | 53.12M shares derived: average of 3 quarters · filed 2026-08-07 | 47.82M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 55.37M shares 10-Q · filed 2026-05-07 | 47.80M shares derived: average of 2 quarters · filed 2026-05-07 | 42.51M shares derived: average of 3 quarters · filed 2026-05-07 | 39.38M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | 40.22M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 36.08M shares derived: average of 2 quarters · filed 2026-03-27 | 34.04M shares derived: average of 3 quarters · filed 2026-08-07 | 32.97M shares 10-K/A · filed 2026-03-27 |
| 2025-09-30 | 31.93M shares 10-Q · filed 2025-11-07 | 30.96M shares derived: average of 2 quarters · filed 2026-08-07 | 30.55M shares 10-Q · filed 2025-11-07 | 30.29M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | 29.98M shares 10-Q · filed 2026-08-07 | 29.84M shares 10-Q · filed 2026-08-07 | 29.75M shares derived: average of 3 quarters · filed 2026-08-07 | 29.67M shares derived: average of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | 29.70M shares 10-Q · filed 2026-05-07 | 29.63M shares derived: average of 2 quarters · filed 2026-05-07 | 29.56M shares derived: average of 3 quarters · filed 2026-05-07 | 29.37M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 29.56M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 29.49M shares derived: average of 2 quarters · filed 2026-03-27 | 29.26M shares derived: average of 3 quarters · filed 2026-03-27 | 28.29M shares 10-K/A · filed 2026-03-27 |
| 2024-09-30 | 29.42M shares 10-Q · filed 2025-11-07 | 29.10M shares derived: average of 2 quarters · filed 2025-11-07 | 27.86M shares 10-Q · filed 2025-11-07 | 25.86M shares derived: average of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | 28.79M shares 10-Q · filed 2025-08-08 | 27.07M shares 10-Q · filed 2025-08-08 | 24.67M shares derived: average of 3 quarters · filed 2025-08-08 | 23.15M shares derived: average of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | 23.44M shares 10-Q · filed 2025-05-08 | 22.61M shares derived: average of 2 quarters · filed 2025-05-08 | 21.27M shares derived: average of 3 quarters · filed 2025-05-08 | 19.71M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 21.78M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 20.18M shares derived: average of 2 quarters · filed 2025-03-25 | 18.47M shares derived: average of 3 quarters · filed 2025-03-25 | 17.34M shares 10-K · filed 2025-03-25 |
| 2023-09-30 | 18.58M shares 10-Q · filed 2024-11-12 | 16.81M shares derived: average of 2 quarters · filed 2024-11-12 | 15.86M shares 10-Q · filed 2024-11-12 | 15.36M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 15.04M shares 10-Q · filed 2024-08-12 | 14.47M shares 10-Q · filed 2024-08-12 | 14.28M shares derived: average of 3 quarters · filed 2024-08-12 | 14.19M shares derived: average of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | 13.90M shares 10-Q · filed 2024-05-09 | 13.90M shares derived: average of 2 quarters · filed 2024-05-09 | 13.91M shares derived: average of 3 quarters · filed 2024-05-09 | 13.90M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 13.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 13.92M shares derived: average of 2 quarters · filed 2024-03-29 | 13.91M shares derived: average of 3 quarters · filed 2024-03-29 | 13.89M shares 10-K · filed 2024-03-29 |
| 2022-09-30 | 13.92M shares 10-Q · filed 2023-11-13 | 13.90M shares derived: average of 2 quarters · filed 2023-11-13 | 13.88M shares 10-Q · filed 2023-11-13 | |
| 2022-06-30 | 13.88M shares 10-Q · filed 2023-08-11 | 13.86M shares 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |